Navigation Links
Renal denervation treats resistant hypertension in real world patient populations
Date:8/27/2012

Munich, Germany August 27 2012: Renal denervation successfully treats patients with resistant hypertension in real world patient populations, according to a study presented at ESC Congress 2012. The findings were presented by Dr Darren Mylotte from France.

Transcatheter renal denervation represents a novel therapy for treating patients with treatment resistant hypertension, a condition which greatly increases the risk of myocardial infarction and stroke.

"The Symplicity Hypertension I and II studies have suggested that this procedure significantly lowers blood pressure in these patients with few remaining options in terms of treatment," said Dr Mylotte. "However, patients included in clinical trials are often highly selected, and therefore may not reflect the patient encountered by physicians on a day-to-day basis. As such, the results of these trials may not be applicable to less-selected patient populations."

In light of this potential problem, the investigators sought to evaluate the effect of transcatheter renal denervation in a group of patients with resistant hypertension in their own clinical practice at The Institut Cardiovasculaire de Paris Sud, Paris, France.

They intended to perform transcatheter renal denervation on 35 consecutive patients referred to the service with resistant hypertension. The study used the same definition as the Symplicity trials to define resistant hypertension (1).

Among these patients, 36.5% were female, 36.4% were diabetic, and 15.2% had kidney dysfunction. Baseline office blood pressure (BP) was 181.121.9 /100.816.8 mmHg, despite an average of 4.61.0 medications per patient. Successful bilateral sympathetic denervation was performed in 33 out of 35 patients (1 patient was not treated due to a stenosis of the renal artery; 1 patient had treatment on one side only, as multiple small renal arteries were found on the other side). No procedural complications occurred.

At 6-months follow-up, the average office BP reduction from baseline was 30.321.1/14.615.3 mmHg (P<0.0001). Similarly, ambulatory BP was reduced 23.312.1/10.29.9 mmHg from baseline (P<0.001). There were no adverse events during follow-up (death, myocardial infarction, or stroke), and no deterioration in renal function was observed.

"Transcatheter renal denervation is a safe and efficacious treatment, which results in significant reductions in blood pressure in real world patients with treatment resistant hypertension," said Dr Mylotte. "Although longer-term results are required, renal denervation should be considered for all patients with treatment resistant hypertension, as it is likely to lower their blood pressure and reduce their chances of myocardial infarction and stroke."


'/>"/>

Contact: ESC Press Office
press@escardio.org
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Newborn Screening May Miss Adrenal-Gland Disorder
2. Broken heart syndrome protects the heart from adrenaline overload
3. Renal denervation gives better outcomes than drugs in advanced heart failure
4. Intense light prevents, treats heart attacks
5. Novel radiation therapy safely treats prostate cancer and lowers the risk of recurrence
6. Kinase test may yield big gains for drug-resistant cancers
7. New drug strategy attacks resistant leukemia and lymphoma
8. Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains
9. New Medicine Might Fight Drug-Resistant TB, Study Says
10. Antibiotic-Resistant Gonorrhea Spreading: WHO
11. Rare Drug-Resistant Bacteria Spotted in U.S. Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... N.J. (PRWEB) , ... January 18, 2017 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... will be presenting at the upcoming WCBP Conference, to be held at the ...
(Date:1/18/2017)... Lebanon, NH (PRWEB) , ... January 18, 2017 ... ... the launch of the revolutionary Active Brake Technology (ABT), an innovative braking system ... stability. , Active Brake Technology addresses one of the biggest concerns of beginner ...
(Date:1/17/2017)... Marne, Michigan (PRWEB) , ... January 17, 2017 , ... January is National Stalking ... those who choose to lurk in the corners and commit the crime of stalking, a ... drug use and addiction, an often overlooked factor in stalking and other crimes. , “Stalking: ...
(Date:1/17/2017)... Angeles, California (PRWEB) , ... January 17, 2017 ... ... to have a point of difference. Eden Activewear is a stand-out company for ... Eden are exclusively online and only manufacture on demand, this is called 'Agile' ...
(Date:1/17/2017)... ... January 17, 2017 , ... Healthful Balance announces ... company, owned and operated by Ed Stroup, was created to offer the highest ... highest level of customer service. Healthful Balance products can be purchased online through ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... LONDON , January 18, 2017 ... community to share research resources, has opened its first North ... . ... This marks an expansion for Ximbio following its launch in ... Cancer Research Technology (CRT), the commercialization arm of the foundation ...
(Date:1/18/2017)... China,s National Regulatory Authority Chinese Food and Drug ... Dynavax Flanders Institute Food and Drug Administration ... Gavi Alliance Glaxo Smith Klein ... Service Bureau, Japan Immune Targeting Systems ... Jenner Institute, University of oxford Johnson & Johnson ...
(Date:1/17/2017)... 2017 EU5 Glucose Monitoring Market Outlook to ... Glucose Monitoring Market Outlook to 2022", provides key market ... provides value, in millions of US dollars, volume (in ... Blood Glucose Meters, Blood Glucose Test Strips and Lancets. ... shares data for each of these market segements, and ...
Breaking Medicine Technology: